The results from the retrospective analyses of data from 4 phase III randomized panitumumab trials showed a worse prognosis for patients with right-versus left-sided RAS wild-type metastatic colorectal cancer (mCRC) receiving second-line or greater therapy. Furthermore, the addition of panitumumab to standard treatment provided benefit to patients with left-sided RAS wild-type tumors. Further research is needed to define the optimal treatment of RAS mutant and right-sided RAS wild-type mCRC. Background: The primary tumor location has a prognostic impact in metastatic colorectal cancer (mCRC). We report the results from retrospective analyses assessing the effect of tumor location on prognosis and efficacy of secondand later-line panitumumab treatment in patients with RAS wild-type (WT) mCRC and on prognosis in all lines of treatment in patients with RAS mutant (MT) mCRC. Patients and Methods: RAS WT data (n ¼ 483) from 2 randomized phase III panitumumab trials (ClinicalTrials.gov identifiers, NCT00339183 and NCT00113763) were analyzed for treatment outcomes stratified by tumor location. The second analysis assessed the effect of tumor location in RAS MT patients (n ¼ 1205) from 4 panitumumab studies (ClinicalTrials.gov identifiers, NCT00364013, NCT00819780, NCT00339183, and NCT00113763). Primary tumors located in the cecum to transverse colon were coded as right-sided; those located from the splenic flexure to the rectum were coded as left-sided. Results: Of all patients, the tumor location was ascertained for 83% to 88%; 71% to 77% of patients had left-sided tumors. RAS WT patients with right-sided tumors did worse for all efficacy parameters compared with those with left-sided tumors. The patients with left-sided tumors had better outcomes with panitumumab than with the comparator treatment. Because of the low patient numbers, no conclusions could be drawn for right-sided mCRC. The prognostic effect of tumor location on survival was unclear for RAS MT patients. Conclusion: These retrospective analyses have confirmed that RAS WT right-sided mCRC is associated with a poor prognosis, regardless of the treatment. RAS WT patients with left-sided tumors benefitted from the addition of panitumumab in second or later treatment lines. Further research is warranted to determine the optimum management of right-sided mCRC and RAS MT tumors.
Introduction
The idea that tumor location had a link with disease biology arose in 1990, when Bufill 1 described colorectal cancer (CRC) by the primary tumor location. Right-sided colon tumors more frequently harbor BRAF mutations, have a higher tumor/nodes/metastases stage at presentation, and have a worse prognosis compared with left-sided colorectal tumors. 2, 3 The fact that the proximal part of the colon is derived from the embryologic midgut, and the distal part and rectum are derived from the embryologic hindgut might help explain the observed differences. Several retrospective analyses have assessed the clinical effect of epidermal growth factor receptor (EGFR)-targeted agents in patients with metastatic CRC (mCRC) according to the primary tumor location, [4] [5] [6] [7] most of which evaluated first-line data from cetuximab trials. [5] [6] [7] These analyses reported better results for cetuximab plus chemotherapy versus chemotherapy alone or combined with bevacizumab in patients with left-sided mCRC. [5] [6] [7] In contrast, patients with right-sided tumors generally appeared to benefit more from chemotherapy combined with bevacizumab. Few data are available on the effect of the tumor location on the efficacy of later-line treatment or in patients with RAS mutant (MT) mCRC. Also, no studies to date have investigated the effect of tumor location on panitumumab efficacy in these settings. The first aim of the present retrospective analyses was to investigate the possible association between primary tumor location and second-or later-line panitumumab efficacy in patients with RAS wild-type (WT) mCRC. The second aim was to assess the effect of tumor location in patients with RAS MT tumors.
Patients and Methods

Study Design and Data Sources
The first analysis was performed on the RAS (KRAS and NRAS exon 2, 3, and 4) WT populations from 2 randomized phase III mCRC trials. The second-line 20050181 trial (ClinicalTrials.gov identifier, NCT00339183) evaluated the effect of panitumumab plus FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) compared with FOLFIRI alone. 8, 9 The later-line 20020408 trial (ClinicalTrials.
gov identifier, NCT00113763) evaluated panitumumab plus best supportive care (BSC) versus BSC alone for patients in whom the available treatment options had failed. 10, 11 This analysis assessed the effect of tumor location on clinical outcomes in the RAS WT and RAS/BRAF WT (after exclusion of all BRAF V600E MT patients) populations. The second analysis studied differences in the clinical outcomes for RAS MT patients with left-and right-sided mCRC from the 2 cited studies and from 2 additional first-line trials: PRIME (ClinicalTrials.gov identifier, NCT00364013), a phase III trial comparing panitumumab plus FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin) versus FOLFOX alone, 12 and PEAK (ClinicalTrials.gov identifier, NCT00819780), a phase II trial comparing panitumumab plus FOLFOX versus bevacizumab plus FOLFOX. 13 
Assessment of Tumor Location
Tumor location information was obtained from the free-text surgery descriptions included in the case report forms and the original pathology reports. Primary tumors located in the cecum to transverse colon were coded as right-sided. Tumors located from the splenic flexure to rectum were categorized as left-sided. The assessors of the tumor location were unaware of the RAS and BRAF mutation status, treatment allocation, and clinical outcomes.
Statistical Analysis
Because these were exploratory, retrospective analyses, no formal hypothesis testing was planned. The efficacy endpoints evaluated were the response rate (RR), duration of response (DoR), progression-free survival (PFS), and overall survival (OS). These endpoints were calculated as previously reported. 14 Data were summarized descriptively. The treatment hazard ratio (HR) for the panitumumab arm relative to the comparator arms and the associated 95% confidence intervals were estimated from a stratified Cox proportional hazard model. Wald tests were used to generate P values. For the RAS WT analysis, the Cox model was adjusted for BRAF status, previous adjuvant therapy, and baseline Eastern Cooperative Oncology Group (ECOG) score (study 20050181) or for BRAF status and baseline ECOG (study 20020408). For the RAS MT analysis, the Cox model was adjusted for the stratification variables as described in the respective study protocols, including region and baseline ECOG (PRIME and study 20020408), previous adjuvant oxaliplatin therapy (PEAK), and region, baseline ECOG, and previous oxaliplatin exposure (study 20050181). No adjustments for BRAF status were made in this population because RAS and BRAF mutations are generally mutually exclusive. Kaplan-Meier curves were generated for all time-toevent endpoints.
Results
Patient Population
The primary tumor location could be determined unequivocally in > 80% of patients in each study ( Table 1 ; available in the online version). In general, the left/right distribution seen in the RAS WT and RAS MT populations was similar to that in the overall study population. However, in the RAS MT population of PEAK, 39% of patients had right-sided mCRC. This RAS MT subgroup was markedly smaller in this study because enrollment in PEAK was restricted to KRAS exon 2 WT patients.
In the RAS WT populations of studies 20050181 (n ¼ 368) and 20020408 (n ¼ 115), BRAF V600E mutations were present in 4% and 6% of patients with left-sided mCRC compared with 31% and 20% of right-sided mCRC patients. No difference was found in age between the left-and right-sided mCRC patients in either the RAS WT ( Figure 1 ). Poor survival was observed in right-sided mCRC patients, and the HRs for OS in both studies demonstrated a worse prognosis for patients with right-sided disease (Supplemental Table 2 ; available in the online version). The prognosis remained poor in the RAS/BRAF WT right-sided population compared with that for those with left-sided tumors, irrespective of the treatment (Supplemental Table 3 ; available in the online version).
Previous adjuvant chemotherapy
RAS MT. In PEAK, RAS MT patients with left-sided tumors had markedly better OS than those with right-sided tumors; however, little to no difference was found in PRIME (Table 4 ). In the laterline trials (studies 20050181 and 20020408), no clear prognostic difference was evident in the RAS MT population. Overall, a prognostic effect of primary tumor location on the HRs for OS was not seen in the RAS MT population (Supplemental Table 4 ; available in the online version).
Predictive Effect of Primary Tumor Location in RAS WT Patients Undergoing Second-or Later-line Treatment
The effect of primary tumor location on the outcomes for RAS WT patients receiving second-or later-line treatment is shown in Table 3 and Figure 1 . In study 20050181, the addition of panitumumab to FOLFIRI resulted in a numerically improved median OS (20.1 vs. 16.6 months; HR, 0.96; P ¼ .7388) and PFS (8.0 vs. 5.8 months; HR, 0.88; P ¼ .3086) compared with FOLFIRI alone in patients with RAS WT left-sided primary tumors. In right-sided mCRC patients, the HR for PFS favored panitumumab (4.8 vs. 2.4 months; HR, 0.75; P ¼ .2859), but the HR for OS favored FOLFIRI (10.3 vs. 8.1 months; HR, 1.14; P ¼ .6193).
In study 20020408, a significant PFS benefit (5.5 vs. 1.6 months; HR, 0.31; P < .0001) was seen when panitumumab was added to BSC for RAS WT left-sided mCRC patients. No difference was found in PFS for patients with right-sided tumors (1.7 vs. 1.5 months; HR, 0.50; P ¼ .1029). The OS results in that study were difficult to interpret because most patients in the BSC arm crossed over to panitumumab at progression (44 of 57 [77%] of the BSC patients with known tumor side status crossed over to panitumumab).
The RRs were greater for the panitumumab versus control arm in the RAS WT left-sided mCRC patients in the 20050181 study (50% vs. 13%) and 20020408 study (24% vs. 0%). In patients with right-sided tumors, the same effect was observed in study 20050181 (13% vs. 3%), but no responses were seen in right-sided mCRC in study 20020408 The effect of primary tumor location on the outcomes for RAS/ BRAF WT patients receiving second-or later-line treatment is shown in Supplemental Table 3 (available in the online version).
PFS, OS, and RR in RAS MT Patients
In PRIME, patients with RAS MT left-sided tumors had a significantly worse median PFS in the panitumumab versus FOL-FOX arm (7.5 vs. 9.4 months; HR, 1.29; P ¼ .0288; Table 4 ), consistent with the results of the study's primary analysis. The same trend was observed for right-sided mCRC patients (7.4 vs. 8.5 months; HR, 1.37; P ¼ .0874). Regarding OS, the HRs favored Table 3 
Effect of Primary Tumor Location in mCRC Patients
FOLFOX for both left-and right-sided RAS MT mCRC patients. No differences between treatments or by location group were observed with respect to RR or DoR.
In PEAK, the results were based on a very small sample size and should therefore be considered with caution. Although left-sided RAS MT mCRC patients had worse median PFS in the panitumumab than in the bevacizumab arm (10.2 vs. 12.0 months; HR, 1.29; P ¼ .4939), the median OS was markedly longer in the panitumumab arm than in the bevacizumab arm (38.3 vs. 22.9 months; HR, 0.55; P ¼ .1871). In right-sided RAS MT mCRC, no difference was found in PFS (7.8 vs. 8.7 months; HR, 1.20; P ¼ .7158), but the median OS favored panitumumab treatment (19.8 vs. 14.1 months; HR, 0.37; P ¼ .0765).
No differences in OS or PFS were observed between treatment arms for left-sided RAS MT mCRC patients in the 20050181 study. In patients with right-sided tumors, the panitumumab arm had better OS (14.1 vs. 10.3 months; HR, 0.57; P ¼ .0027), although no difference was found in PFS (5.6 vs. 5.3 months; HR, 0.77; P ¼ .1500). The median OS appeared to be better in the panitumumab arm in RAS MT right-sided mCRC (14.1 months) than left-sided mCRC (11.3 months).
In the 20020408 study, no difference in PFS between treatments in either RAS MT tumor location subgroup was observed.
Discussion
To the best of our knowledge, the present study is the first to report the effect of primary tumor location on clinical outcomes during second-or later-line panitumumab treatment. Our results also provide valuable location data for the RAS MT cohorts from 4 randomized panitumumab mCRC trials, which have not been explored previously.
Our analyses found prognostic effects in both patients with RAS WT and patients with RAS/BRAF WT tumors, confirming the prognostic effect of tumor location in second and later treatment lines that was previously reported for the first-line setting. 5, 7, 14 As was seen in the retrospective analysis of data from the first-line panitumumab studies, 15 RAS WT patients with right-sided primary tumors had worse prognosis than those with left-sided tumors in later lines of mCRC treatment. To the best of our knowledge, the present study is the first to demonstrate a prognostic effect beyond first-line treatment in RAS WT patients. The observed prognostic effect of tumor location in the second-and later-line RAS/BRAF WT population has confirmed that the worse prognosis of rightsided primary tumors does not only result from the presence of BRAF mutations, as has been reported previously. 16 To date, most studies assessing the predictive effect of tumor location on the efficacy of anti-EGFR therapy have focused on cetuximab data and have yielded results similar to those from the present analyses.
In the present report, we found that patients with RAS WT left-sided primary tumors benefitted from the addition of panitumumab to chemotherapy or BSC. In the second-line 20050181 study, despite numeric PFS and RR benefits in right-sided RAS WT mCRC with the addition of panitumumab, the OS HR appeared to favor FOLFIRI alone (P ¼ NS). Patients with right-sided mCRC undergoing secondline treatment had very low RRs, especially in the FOLFIRI arm. In the 20020408 trial, the addition of panitumumab to BSC resulted in better PFS for patients with left-sided RAS WT mCRC, which was also reflected by an improved RR, and once again, the very poor prognosis of right-sided mCRC was confirmed. Few data have been reported on the effect of primary tumor location in RAS MT mCRC. In our analyses, the prognostic effect of tumor location in patients with RAS mutations was not clear. Regarding the predictive effect, we found better outcomes favoring the FOLFOX arm in patients with left-and right-sided mCRC in the first-line PRIME trial. These results were not surprising, because they were in line with the study's primary analysis. In the PEAK study, the results should be considered with caution owing to the low number of patients with RAS MT tumors (recruitment was limited to patients with KRAS exon 2 WT tumors in that study). In patients with leftsided RAS MT primary tumors, the median OS in the panitumumab arm was > 50% longer than that seen for bevacizumab; similar results were seen for patients with right-sided primary tumors. These results were unexpected because, although RAS MT tumors are known to be resistant to anti-EGFR therapy, this small subgroup of patients did not appear to clearly benefit more from the addition of bevacizumab. These results are consistent with those reported from the first-line CALGB/SWOG (Cancer and Leukemia Group B/ Southwestern Oncology Group) 80405 trial 7 and FIRE-3 (FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer) trials, 17 in which OS was not significantly different statistically between cetuximab and bevacizumab. In the 20050181 study, the OS for patients with rightsided primary tumors appeared better for the panitumumab arm than for the FOLFIRI arm in RAS MT patients. This could be a chance finding, but an alternative hypothesis is whether first-line treatment might induce clonal selection, making some patients more sensitive to anti-EGFR treatment. Validation of these findings in other cohorts is necessary to draw definitive conclusions regarding the optimum treatment of patients with RAS MT tumors. The present study was limited by its retrospective nature and the relatively small number of patients with right-sided primary tumors. Therefore, definitive conclusions could not be drawn regarding the optimum treatment of right-sided mCRC. It would also be useful to assess the effect of biomarkers other than RAS and BRAF, because these could also affect clinical outcomes. These analyses were, nonetheless, strengthened by the high tumor location and RAS/BRAF ascertainment rates. The assessors of tumor location were also kept unaware of the RAS/ BRAF mutation status, treatment allocation, and clinical outcomes.
Conclusion
Panitumumab plus chemotherapy or BSC provided better clinical outcomes compared with chemotherapy or BSC alone in RAS WT patients with left-sided primary tumors receiving second-or laterline treatment. Because of the relatively small number of patients with right-sided tumors, it was not possible to draw definitive conclusions on the optimal treatment. In view of these and other recently reported findings, tumor location should be considered during treatment decision-making. Further research is needed regarding the optimal treatment of patients with right-sided primary tumors and those with RAS MT mCRC.
Clinical Practice Points
During the past decade, several studies have investigated the clinical effect of primary tumor location in CRC, and it has been reported that patients with right-sided disease have a worse prognosis than patients with left-sided disease. Recently, researchers also evaluated the predictive value of tumor location in the treatment of CRC, with most of these studies focusing on data from first-line cetuximab trials. In addition, another study from our research group has addressed the effect of primary tumor location on panitumumab treatment in 2 first-line studies. We have reported tumor location data from 2 studies of panitumumab after the first treatment line; to the best of our knowledge, ours is the first study to investigate the effect of tumor location in second-and later-line panitumumab studies. The results of these analyses have confirmed the negative prognostic effect of right-sided disease in RAS WT patients undergoing second-and later-line treatment. In addition, we found that patients with RAS WT left-sided disease benefit from the addition of panitumumab to chemotherapy or BSC compared with chemotherapy or BSC alone. These results are in line with those recently reported from firstline cetuximab and panitumumab studies, showing that patients with left-sided disease benefit from the addition of cetuximab or panitumumab, respectively. Our data on right-sided and RAS MT disease are inconclusive and require further investigation. Nevertheless, it is clear that tumor location is clinically important and should be considered during treatment decision-making. 
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